Platelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents

A significant proportion of older patients with immune thrombocytopenia (ITP) also have clinical indications for treatment of cardiovascular disease with antiplatelet agents. Ollier and colleagues sought to determine the frequency of bleeding in patients with ITP on aspirin therapy, finding that the...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-09, Vol.142 (12), p.1099-1101
Main Authors: Ollier, Natasha, Piel-Julian, Marie-Léa, Mahévas, Matthieu, Viallard, Jean-François, Comont, Thibault, Chèze, Stéphane, Audia, Sylvain, Ebbo, Mikaël, Terriou, Louis, Lega, Jean-Christophe, Jeandel, Pierre-Yves, Bonnotte, Bernard, Michel, Marc, Lapeyre-Mestre, Maryse, Godeau, Bertrand, Moulis, Guillaume
Format: Article
Language:English
Subjects:
Hemorrhage - chemically induced
Humans
Platelet Aggregation Inhibitors - adverse effects
Platelet Count
Purpura, Thrombocytopenic, Idiopathic - drug therapy
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A significant proportion of older patients with immune thrombocytopenia (ITP) also have clinical indications for treatment of cardiovascular disease with antiplatelet agents. Ollier and colleagues sought to determine the frequency of bleeding in patients with ITP on aspirin therapy, finding that the pattern of bleeding, segregated by platelet count, is similar to that observed in other adults with ITP not on aspirin. They show that a platelet count of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2023020311